Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Pharmacological Treatments for Diabetic Foot Disease: Current State and Future Perspectives

Author(s): Prashanth R.J. Vas*, Erika Vainieri and Natasha Patel

Volume 27, Issue 8, 2021

Published on: 07 December, 2020

Page: [1080 - 1092] Pages: 13

DOI: 10.2174/1381612826666201207102423

Price: $65

Abstract

The care of the individual with diabetic foot disease (DFD) represents a significant challenge. In addition to the primary foot pathology, individuals with DFD are frequently compromised by multiple co-existent medical complications. Successful management of DFD, therefore requires simultaneous addressal of these issues alongside high-quality foot care. We explore the pharmacological treatments in DFD with an emphasis on the emerging putative technologies centred on addressing the pathobiology of wound healing but also discuss developments in infection control, Charcot neuroarthropathy, cardiovascular and diabetes care. Many of these will have a significant impact on future treatment paradigms and how we amalgamate these novel technologies may help shape the standard of care in DFD hereafter. However, there is a need for better quality of evidence and cost-effectiveness data prior to widespread adoption into routine care is considered.

Keywords: Diabetic foot disease, diabetic foot ulcer, wound healing, cardiovascular risk, glycaemic control, charcot foot, pharmacotherapy in diabetic foot.

« Previous Next »
[1]
van Netten JJ, Bus SA, Apelqvist J, et al. International Working Group on the Diabetic Foot. Definitions and criteria for diabetic foot disease. Diabetes Metab Res Rev 2020; 36(Suppl. 1)
[http://dx.doi.org/10.1002/dmrr.3268] [PMID: 31943705]
[2]
Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med 2017; 376(24): 2367-75.
[http://dx.doi.org/10.1056/NEJMra1615439] [PMID: 28614678]
[3]
Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis†. Ann Med 2017; 49(2): 106-16.
[http://dx.doi.org/10.1080/07853890.2016.1231932] [PMID: 27585063]
[4]
Boulton AJM, Armstrong DG, Kirsner RS, et al. Diagnosis and management of diabetic foot complications. Diabetes 2018; 2018(2): 1-20.
[http://dx.doi.org/10.2337/db20182-1] [PMID: 30958663]
[5]
Metcalf L, Musgrove M, Bentley J, et al. Prevalence of active Charcot disease in the East Midlands of England. Diabet Med 2018; 35(10): 1371-4.
[http://dx.doi.org/10.1111/dme.13679] [PMID: 29782669]
[6]
Kerr M, Barron E, Chadwick P, et al. The cost of diabetic foot ulcers and amputations to the National Health Service in England. Diabet Med 2019; 36(8): 995-1002.
[http://dx.doi.org/10.1111/dme.13973] [PMID: 31004370]
[7]
Zhang Y, Lazzarini PA, McPhail SM, van Netten JJ, Armstrong DG, Pacella RE. Global Disability Burdens of Diabetes-Related Lower-Extremity Complications in 1990 and 2016. Diabetes Care 2020; 43(5): 964-74.
[http://dx.doi.org/10.2337/dc19-1614] [PMID: 32139380]
[8]
Ismail K, Winkley K, Stahl D, Chalder T, Edmonds M. A cohort study of people with diabetes and their first foot ulcer: the role of depression on mortality. Diabetes Care 2007; 30(6): 1473-9.
[http://dx.doi.org/10.2337/dc06-2313] [PMID: 17363754]
[9]
Natovich R, Kushnir T, Harman-Boehm I, et al. Cognitive Dysfunction: Part and Parcel of the Diabetic Foot. Diabetes Care 2016; 39(7): 1202-7.
[http://dx.doi.org/10.2337/dc15-2838] [PMID: 27208339]
[10]
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366(9498): 1736-43.
[http://dx.doi.org/10.1016/S0140-6736(05)67700-8] [PMID: 16291068]
[11]
Hu SC, Lan CE. High-glucose environment disturbs the physiologic functions of keratinocytes: Focusing on diabetic wound healing. J Dermatol Sci 2016; 84(2): 121-7.
[http://dx.doi.org/10.1016/j.jdermsci.2016.07.008] [PMID: 27461757]
[12]
Jeffcoate WJ, Price P, Harding KG. International Working Group on Wound Healing and Treatments for People with Diabetic Foot Ulcers. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 2004; 20(Suppl. 1): S78-89.
[http://dx.doi.org/10.1002/dmrr.476] [PMID: 15150819]
[13]
Digital N. National Diabetes Foot Care Audit Report 2014-2016 2017. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-footcare-audit/national-diabetes-foot-care-audit-2014-2016
[14]
Prompers L, Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008; 51(5): 747-55.
[http://dx.doi.org/10.1007/s00125-008-0940-0] [PMID: 18297261]
[15]
Fife CE, Eckert KA, Carter MJ. Publicly Reported Wound Healing Rates: The Fantasy and the Reality. Adv Wound Care (New Rochelle) 2018; 7(3): 77-94.
[http://dx.doi.org/10.1089/wound.2017.0743] [PMID: 29644145]
[16]
Siersma V, Thorsen H, Holstein PE, et al. Health-related quality of life predicts major amputation and death, but not healing, in people with diabetes presenting with foot ulcers: the Eurodiale study. Diabetes Care 2014; 37(3): 694-700.
[http://dx.doi.org/10.2337/dc13-1212] [PMID: 24170755]
[17]
Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med 2018; 35(1): 78-88.
[http://dx.doi.org/10.1111/dme.13537] [PMID: 29083500]
[18]
Walsh JW, Hoffstad OJ, Sullivan MO, Margolis DJ. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med 2016; 33(11): 1493-8.
[http://dx.doi.org/10.1111/dme.13054] [PMID: 26666583]
[19]
Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007; 4(4): 286-7.
[http://dx.doi.org/10.1111/j.1742-481X.2007.00392.x] [PMID: 18154621]
[20]
Rayman G, Vas P, Dhatariya K, et al. International Working Group on the Diabetic Foot (IWGDF). Guidelines on use of interventions to enhance healing of chronic foot ulcers in diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36(Suppl. 1)
[http://dx.doi.org/10.1002/dmrr.3283] [PMID: 32176450]
[21]
Motley TA, Lange DL, Dickerson JE Jr, Slade HB. Clinical outcomes associated with serial sharp debridement of diabetic foot ulcers with and without clostridial collagenase ointment. Wounds 2014; 26(3): 57-64.
[PMID: 25860329]
[22]
Tallis A, Motley TA, Wunderlich RP, Dickerson JE Jr, Waycaster C, Slade HB. Collagenase Diabetic Foot Ulcer Study Group. Clinical and economic assessment of diabetic foot ulcer debridement with collagenase: results of a randomized controlled study. Clin Ther 2013; 35(11): 1805-20.
[http://dx.doi.org/10.1016/j.clinthera.2013.09.013] [PMID: 24145042]
[23]
Motley TA, Caporusso JM, Lange DL, Eichelkraut RA, Cargill DI, Dickerson JE Jr. Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver. Adv Wound Care (New Rochelle) 2018; 7(10): 339-48.
[http://dx.doi.org/10.1089/wound.2018.0784] [PMID: 30374419]
[24]
Jull AB, Cullum N, Dumville JC, Westby MJ, Deshpande S, Walker N. Honey as a topical treatment for wounds. Cochrane Database Syst Rev 2015; (3):
[http://dx.doi.org/10.1002/14651858.CD005083.pub4] [PMID: 25742878]
[25]
Catrina SB, Zheng X. Disturbed hypoxic responses as a pathogenic mechanism of diabetic foot ulcers. Diabetes Metab Res Rev 2016; 32(S1): 179-85.
[http://dx.doi.org/10.1002/dmrr.2742]
[26]
Bishop A. Role of oxygen in wound healing. J Wound Care 2008; 17(9): 399-402.
[http://dx.doi.org/10.12968/jowc.2008.17.9.30937] [PMID: 18833899]
[27]
Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res 2010; 89(3): 219-29.
[http://dx.doi.org/10.1177/0022034509359125] [PMID: 20139336]
[28]
Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg 2016; 63(2)(Suppl.): 3S-21S.
[http://dx.doi.org/10.1016/j.jvs.2015.10.003] [PMID: 26804367]
[29]
Gottrup F, Dissemond J, Baines C, Frykberg R, Jensen PO, Kot J, et al. Use of Oxygen Therapies in Wound Healing J Wound Care 2017; 26(Sup5): S1-S43.
[30]
Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010; 33(5): 998-1003.
[http://dx.doi.org/10.2337/dc09-1754] [PMID: 20427683]
[31]
Fedorko L, Bowen JM, Jones W, et al. Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. Diabetes Care 2016; 39(3): 392-9.
[http://dx.doi.org/10.2337/dc15-2001] [PMID: 26740639]
[32]
Santema KTB, Stoekenbroek RM, Koelemay MJW, et al. DAMO2CLES Study Group. Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower- Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial. Diabetes Care 2018; 41(1): 112-9.
[PMID: 29074815]
[33]
Brouwer RJ, Lalieu RC, Hoencamp R, van Hulst RA, Ubbink DT. A systematic review and meta-analysis of hyperbaric oxygen therapy for diabetic foot ulcers with arterial insufficiency. J Vasc Surg 2020; 71(2): 682-92.
[34]
Vas PR, Papanas N. Editorial and Mini-Review: Topical Oxygen Therapy for Diabetic Foot Ulcerations - Avenue Towards New Hope? Rev Diabet Stud 2019; 15: 71-3.
[http://dx.doi.org/10.1900/RDS.2019.15.71] [PMID: 31904758]
[35]
Niederauer MQ, Michalek JE, Armstrong DGAA. Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen Therapy to Sham Therapy in the Treatment of Diabetic Foot Ulcers. J Diabetes Sci Technol 2017; 11(5): 883-91.
[http://dx.doi.org/10.1177/1932296817695574] [PMID: 28654304]
[36]
Niederauer MQ, Michalek JE, Liu Q, Papas KK, Lavery LA, Armstrong DG. Continuous diffusion of oxygen improves diabetic foot ulcer healing when compared with a placebo control: a randomised, double-blind, multicentre study Journal of wound care 2018; 27(Sup9): S30-45.
[http://dx.doi.org/10.12968/jowc.2018.27.Sup9.S30]
[37]
Driver VR, Reyzelman A, Kawalec J, French MA. Prospective, Randomized, Blinded, Controlled Trial Comparing Transdermal Continuous Oxygen Delivery to Moist Wound Therapy for the Treatment of Diabetic Foot Ulcers. Ostomy Wound Manage 2017; 63(4): 12-28.
[PMID: 28448266]
[38]
Frykberg RG, Franks PJ, Edmonds M, et al. TWO2 Study Group. A Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study. Diabetes Care 2020; 43(3): 616-24.
[http://dx.doi.org/10.2337/dc19-0476] [PMID: 31619393]
[39]
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69(3): 562-73.
[http://dx.doi.org/10.1016/j.cardiores.2005.12.002] [PMID: 16405877]
[40]
Quintero-Fabián S, Arreola R, Becerril-Villanueva E, et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol 2019; 9(1370): 1370.
[http://dx.doi.org/10.3389/fonc.2019.01370] [PMID: 31921634]
[41]
Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol 2018; 6(3): 186-96.
[http://dx.doi.org/10.1016/S2213-8587(17)30438-2] [PMID: 29275068]
[42]
Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16(5): 585-601.
[http://dx.doi.org/10.1111/j.1524-475X.2008.00410.x] [PMID: 19128254]
[43]
Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83(3): 835-70.
[http://dx.doi.org/10.1152/physrev.2003.83.3.835] [PMID: 12843410]
[44]
Zarei F, Soleimaninejad M. Role of growth factors and biomaterials in wound healing. Artif Cells Nanomed Biotechnol 2018; 46(Suppl. 1): 906-11.
[http://dx.doi.org/10.1080/21691401.2018.1439836]
[45]
Steed DL. Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21(1): 71-8.
[http://dx.doi.org/10.1016/S0741-5214(95)70245-8] [PMID: 7823364]
[46]
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21(5): 822-7.
[http://dx.doi.org/10.2337/diacare.21.5.822] [PMID: 9589248]
[47]
Landsman A, Agnew P, Parish L, Joseph R, Galiano RD. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis. J Am Podiatr Med Assoc 2010; 100(3): 155-60.
[http://dx.doi.org/10.7547/1000155] [PMID: 20479444]
[48]
Khandelwal S, Chaudhary P, Poddar DD, Saxena N, Singh RA, Biswal UC. Comparative Study of Different Treatment Options of Grade III and IV Diabetic Foot Ulcers to Reduce the Incidence of Amputations. Clin Pract 2013; 3(1)
[PMID: 24765502]
[49]
D’Hemecourt PA. Sodium carboxymethylcellulose aqueous-bared gel vs. becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds 1998; 10: 69-75.
[50]
Ma C, Hernandez MA, Kirkpatrick VE, Liang LJ, Nouvong AL, Gordon II. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial. Wounds 2015; 27(4): 83-91.
[PMID: 25855851]
[51]
Driver VR, Hanft J, Fylling CP, Beriou JM. 2, 4 passim. Autologel Diabetic Foot Ulcer Study G. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006; 52(6): 68-70.
[52]
Del Pino-Sedeño T, Trujillo-Martín MM, Andia I, et al. Platelet-rich plasma for the treatment of diabetic foot ulcers: A meta-analysis. Wound Repair Regen 2019; 27(2): 170-82.
[http://dx.doi.org/10.1111/wrr.12690] [PMID: 30575212]
[53]
Hu Z, Qu S, Zhang J, et al. Efficacy and Safety of Platelet-Rich Plasma for Patients with Diabetic Ulcers: A Systematic Review and Meta-analysis. Adv Wound Care (New Rochelle) 2019; 8(7): 298-308.
[http://dx.doi.org/10.1089/wound.2018.0842] [PMID: 31832277]
[54]
Game F, Jeffcoate W, Tarnow L, et al. LeucoPatch II trial team. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6(11): 870-8.
[http://dx.doi.org/10.1016/S2213-8587(18)30240-7] [PMID: 30243803]
[55]
Frykberg RG, Gibbons GW, Walters JL, Wukich DK, Milstein FC. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. Int Wound J 2017; 14(3): 569-77.
[http://dx.doi.org/10.1111/iwj.12649] [PMID: 27489115]
[56]
Raspovic KM, Wukich DK, Naiman DQ, et al. Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting. Wound Repair Regen 2018; 26(2): 213-20.
[http://dx.doi.org/10.1111/wrr.12635] [PMID: 29683538]
[57]
Tettelbach W, Cazzell S, Sigal F, et al. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. Int Wound J 2019; 16(1): 122-30.
[http://dx.doi.org/10.1111/iwj.13001] [PMID: 30246926]
[58]
Vas P, Rayman G, Dhatariya K, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review Diabetes Metab Res Rev 2020; 36(Suppl. 1)
[http://dx.doi.org/10.1002/dmrr.3284] [PMID: 32176446]
[59]
Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26(6): 1856-61.
[http://dx.doi.org/10.2337/diacare.26.6.1856] [PMID: 12766123]
[60]
Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, et al. Cuban Diabetic Foot Study Group. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J 2009; 6(6): 432-43.
[http://dx.doi.org/10.1111/j.1742-481X.2009.00641.x] [PMID: 20051095]
[61]
Mansbridge JN, Liu K, Pinney RE, Patch R, Ratcliffe A, Naughton GK. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes Obes Metab 1999; 1(5): 265-79.
[http://dx.doi.org/10.1046/j.1463-1326.1999.00032.x] [PMID: 11225638]
[62]
Han SK, Kim HS, Kim WK. Efficacy and safety of fresh fibroblast allografts in the treatment of diabetic foot ulcers. Dermatol Surg 2009; 35(9): 1342-8.
[http://dx.doi.org/10.1111/j.1524-4725.2009.01239.x] [PMID: 19500128]
[63]
Ananian CE, Dhillon YS, Van Gils CC, et al. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers. Wound Repair Regen 2018; 26(3): 274-83.
[http://dx.doi.org/10.1111/wrr.12645] [PMID: 30098272]
[64]
Xu J, Min D, Guo G, Liao X, Fu Z. Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds. Exp Ther Med 2018; 15(6): 5365-70.
[http://dx.doi.org/10.3892/etm.2018.6131] [PMID: 29904416]
[65]
Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350(9081): 855-9.
[http://dx.doi.org/10.1016/S0140-6736(97)04495-4] [PMID: 9310604]
[66]
Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28(9): 2155-60.
[http://dx.doi.org/10.2337/diacare.28.9.2155] [PMID: 16123483]
[67]
Marston WA, Hanft J, Norwood P, Pollak R. Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003; 26(6): 1701-5.
[http://dx.doi.org/10.2337/diacare.26.6.1701] [PMID: 12766097]
[68]
Edmonds ME, Foster AV, McColgan M. ‘Dermagraft’: a new treatment for diabetic foot ulcers. Diabet Med 1997; 14(12): 1010-1.
[http://dx.doi.org/10.1002/(SICI)1096-9136(199712)14:12<1010:AID-DIA549>3.0.CO;2-N] [PMID: 9455927]
[69]
Veves A, Falanga V, Armstrong DG, Sabolinski ML, Apligraf Diabetic Foot Ulcer S. Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24(2): 290-5.
[http://dx.doi.org/10.2337/diacare.24.2.290] [PMID: 11213881]
[70]
Steinberg JS, Edmonds M, Hurley DP Jr, King WN. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc 2010; 100(1): 73-7.
[http://dx.doi.org/10.7547/1000073] [PMID: 20093548]
[71]
Lipsky BA, Senneville É, Abbas ZG, et al. International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36(Suppl. 1)
[http://dx.doi.org/10.1002/dmrr.3280] [PMID: 32176444]
[72]
Atiyeh BS, Dibo SA, Hayek SN. Wound cleansing, topical antiseptics and wound healing. Int Wound J 2009; 6(6): 420-30.
[http://dx.doi.org/10.1111/j.1742-481X.2009.00639.x] [PMID: 20051094]
[73]
Drosou A, Falabella A, Kirsner RS. Antiseptics on wounds: an area of controversy. Wounds 2003; 15(5): 149-66.
[74]
Jeffcoate WJ, Price PE, Phillips CJ, et al. Randomised controlled trial of the use of three dressing preparations in the management of chronic ulceration of the foot in diabetes. Health Technol Assess 2009; 13(54): 1-86.
[http://dx.doi.org/10.3310/hta13540] [PMID: 19922726]
[75]
Zhu G, Wang Q, Lu S, Niu Y. Hydrogen Peroxide: A Potential Wound Therapeutic Target? Med Princ Pract 2017; 26(4): 301-8.
[http://dx.doi.org/10.1159/000475501] [PMID: 28384636]
[76]
Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers Cochrane Database Syst Rev 2006; (1):
[http://dx.doi.org/10.1002/14651858.CD005082.pub2] [PMID: 16437516]
[77]
Delgado-Enciso I, Madrigal-Perez VM, Lara-Esqueda A, et al. Topical 5% potassium permanganate solution accelerates the healing process in chronic diabetic foot ulcers. Biomed Rep 2018; 8(2): 156-9.
[http://dx.doi.org/10.3892/br.2018.1038] [PMID: 29435274]
[78]
Lipsky BA, Berendt AR, Cornia PB, et al. Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54(12): e132-73.
[http://dx.doi.org/10.1093/cid/cis346] [PMID: 22619242]
[79]
Li HK, Rombach I, Zambellas R, et al. OVIVA Trial Collaborators. Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med 2019; 380(5): 425-36.
[http://dx.doi.org/10.1056/NEJMoa1710926] [PMID: 30699315]
[80]
Scarborough M, Li HK, Rombach I, et al. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. Health Technol Assess 2019; 23(38): 1-92.
[http://dx.doi.org/10.3310/hta23380] [PMID: 31373271]
[81]
Vas PRJ, Demetriou M, Papanas N. Oral antibiotic therapy in diabetic foot osteomyelitis: one small step or a giant leap of faith? Ann Transl Med 2019; 7(Suppl. 8): S266.
[http://dx.doi.org/10.21037/atm.2019.12.53] [PMID: 32015985]
[82]
Howlin RP, Brayford MJ, Webb JS, Cooper JJ, Aiken SS, Stoodley P. Antibiotic-loaded synthetic calcium sulfate beads for prevention of bacterial colonization and biofilm formation in periprosthetic infections. Antimicrob Agents Chemother 2015; 59(1): 111-20.
[http://dx.doi.org/10.1128/AAC.03676-14] [PMID: 25313221]
[83]
Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J Foot Ankle Surg 2000; 39(2): 124-30.
[http://dx.doi.org/10.1016/S1067-2516(00)80037-X] [PMID: 10789104]
[84]
Markakis K, Faris AR, Sharaf H, Faris B, Rees S, Bowling FL. Local Antibiotic Delivery Systems: Current and Future Applications for Diabetic Foot Infections. Int J Low Extrem Wounds 2018; 17(1): 14-21.
[http://dx.doi.org/10.1177/1534734618757532] [PMID: 29458291]
[85]
Ferguson J, Diefenbeck M, McNally M. Ceramic Biocomposites as Biodegradable Antibiotic Carriers in the Treatment of Bone Infections. J Bone Jt Infect 2017; 2(1): 38-51.
[http://dx.doi.org/10.7150/jbji.17234] [PMID: 28529863]
[86]
Jogia RM, Modha DE, Nisal K, Berrington R, Kong MF. Use of highly purified synthetic calcium sulfate impregnated with antibiotics for the management of diabetic foot ulcers complicated by osteomyelitis. Diabetes Care 2015; 38(5): e79-80.
[http://dx.doi.org/10.2337/dc14-3100] [PMID: 25908163]
[87]
Drampalos E, Mohammad HR, Kosmidis C, Balal M, Wong J, Pillai A. Single stage treatment of diabetic calcaneal osteomyelitis with an absorbable gentamicin-loaded calcium sulphate/hydroxyapatite biocomposite: The Silo technique. Foot 2018; 34: 40-4.
[http://dx.doi.org/10.1016/j.foot.2017.11.011] [PMID: 29278835]
[88]
Lipsky BA, Kuss M, Edmonds M, Reyzelman A, Sigal F. Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial. J Am Podiatr Med Assoc 2012; 102(3): 223-32.
[http://dx.doi.org/10.7547/1020223] [PMID: 22659765]
[89]
Chantelau E. The perils of procrastination: effects of early vs. delayed detection and treatment of incipient Charcot fracture. Diabet Med 2005; 22(12): 1707-12.
[http://dx.doi.org/10.1111/j.1464-5491.2005.01677.x] [PMID: 16401316]
[90]
Game FL, Catlow R, Jones GR, et al. Audit of acute Charcot’s disease in the UK: the CDUK study. Diabetologia 2012; 55(1): 32-5.
[http://dx.doi.org/10.1007/s00125-011-2354-7] [PMID: 22065087]
[91]
Petrova NL, Edmonds ME. Conservative and Pharmacologic Treatments for the Diabetic Charcot Foot. Clin Podiatr Med Surg 2017; 34(1): 15-24.
[http://dx.doi.org/10.1016/j.cpm.2016.07.003] [PMID: 27865311]
[92]
Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot’s osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008; 51(6): 1035-40.
[http://dx.doi.org/10.1007/s00125-008-0992-1] [PMID: 18389210]
[93]
Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001; 44(11): 2032-7.
[http://dx.doi.org/10.1007/s001250100008] [PMID: 11719835]
[94]
Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 2005; 28(5): 1214-5.
[http://dx.doi.org/10.2337/diacare.28.5.1214] [PMID: 15855594]
[95]
Pakarinen TK, Laine HJ, Mäenpää H, Mattila P, Lahtela J. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. Diabetes Care 2011; 34(7): 1514-6.
[http://dx.doi.org/10.2337/dc11-0396] [PMID: 21593295]
[96]
Bem R, Jirkovská A, Fejfarová V, Skibová J, Jude EB. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care 2006; 29(6): 1392-4.
[http://dx.doi.org/10.2337/dc06-0376] [PMID: 16732029]
[97]
Busch-Westbroek TE, Delpeut K, Balm R, et al. Effect of Single Dose of RANKL Antibody Treatment on Acute Charcot Neuro-osteoarthropathy of the Foot. Diabetes Care 2018; 41(3): e21-2.
[http://dx.doi.org/10.2337/dc17-1517] [PMID: 29273577]
[98]
Forsythe RO, Apelqvist J, Boyko EJ, et al. Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: A systematic review Diabetes Metab Res Rev 2020; 36(Suppl. 1)
[http://dx.doi.org/10.1002/dmrr.3277] [PMID: 32176448]
[99]
Hinchliffe RJ, Brownrigg JR, Apelqvist J, et al. International Working Group on the Diabetic Foot. IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes. Diabetes Metab Res Rev 2016; 32(Suppl. 1): 37-44.
[http://dx.doi.org/10.1002/dmrr.2698] [PMID: 26332424]
[100]
Hinchliffe RJ, Forsythe RO, Apelqvist J, et al. International Working Group on the Diabetic Foot (IWGDF). Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36(Suppl. 1)
[http://dx.doi.org/10.1002/dmrr.3276] [PMID: 31958217]
[101]
Aboyans V, Ricco JB, Bartelink MEL, et al. Editor’s Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018; 55(3): 305-68.
[http://dx.doi.org/10.1016/j.ejvs.2017.07.018] [PMID: 28851596]
[102]
Navarese EP, Wernly B, Lichtenauer M, et al. Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. Int J Cardiol 2018; 269: 292-7.
[http://dx.doi.org/10.1016/j.ijcard.2018.07.009] [PMID: 30045826]
[103]
Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA, Investigators C. CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30(2): 192-201.
[http://dx.doi.org/10.1093/eurheartj/ehn534] [PMID: 19136484]
[104]
Connolly SJ, Eikelboom JW, Bosch J, et al. COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391(10117): 205-18.
[http://dx.doi.org/10.1016/S0140-6736(17)32458-3] [PMID: 29132879]
[105]
Bhatt DL, Eikelboom JW, Connolly SJ, et al. COMPASS Steering Committee and Investigators. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation 2020; 141(23): 1841-54.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046448] [PMID: 32223318]
[106]
Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 2020; 382(21): 1994-2004.
[http://dx.doi.org/10.1056/NEJMoa2000052] [PMID: 32222135]
[107]
Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[108]
Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb Cochrane Database Syst Rev 2007; (4):
[http://dx.doi.org/10.1002/14651858.CD000123.pub2] [PMID: 17943736]
[109]
Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017; 2(1): 47-54.
[http://dx.doi.org/10.1001/jamacardio.2016.4052] [PMID: 27829091]
[110]
Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 2016; 11(11)
[http://dx.doi.org/10.1002/14651858.CD009753.pub2] [PMID: 27849333]
[111]
Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke Cochrane Database Syst Rev 2015; (10):
[http://dx.doi.org/10.1002/14651858.CD009580.pub2] [PMID: 26497361]
[112]
Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-27.
[PMID: 22910633]
[113]
Johansen OE, Birkeland KI, Jørgensen AP, et al. Diabetic foot ulcer burden may be modified by high-dose atorvastatin: A 6-month randomized controlled pilot trial. J Diabetes 2009; 1(3): 182-7.
[http://dx.doi.org/10.1111/j.1753-0407.2009.00031.x] [PMID: 20923537]
[114]
Fox JD, Baquerizo-Nole KL, Macquhae F, et al. Statins may be associated with six-week diabetic foot ulcer healing. Wound Repair Regen 2016; 24(2): 454-7.
[http://dx.doi.org/10.1111/wrr.12400] [PMID: 26748844]
[115]
Rajamani K, Colman PG, Li LP, et al. FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373(9677): 1780-8.
[http://dx.doi.org/10.1016/S0140-6736(09)60698-X] [PMID: 19465233]
[116]
Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383(9911): 60-8.
[http://dx.doi.org/10.1016/S0140-6736(13)61914-5] [PMID: 24094767]
[117]
Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014; 11(10): 563-75.
[http://dx.doi.org/10.1038/nrcardio.2014.84] [PMID: 24958078]
[118]
Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[119]
Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379(22): 2097-107.
[http://dx.doi.org/10.1056/NEJMoa1801174] [PMID: 30403574]
[120]
Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018; 137(4): 338-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032235] [PMID: 29133605]
[121]
American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43(Suppl. 1): S111-34.
[http://dx.doi.org/10.2337/dc20-S010] [PMID: 31862753]
[122]
National Institute of Health and Care Excellence Diabetes - type 2 Available at: https://cks.nice.org.uk/topics/diabetes-type-2/management/management-adults/2019
[123]
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405-12.
[http://dx.doi.org/10.1136/bmj.321.7258.405] [PMID: 10938048]
[124]
Pop-Busui R, Herman WH, Feldman EL, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010; 10(4): 276-82.
[http://dx.doi.org/10.1007/s11892-010-0120-8] [PMID: 20464532]
[125]
Lane KL, Abusamaan MS, Voss BF, et al. Glycemic control and diabetic foot ulcer outcomes: A systematic review and meta-analysis of observational studies. J Diabetes Complications 2020; 34(10)
[http://dx.doi.org/10.1016/j.jdiacomp.2020.107638] [PMID: 32527671]
[126]
Vas PRJ, Whyte MB, Papanas N. Association between glycaemic control and diabetic foot outcomes: Dark side of the moon? J Diabetes Complications 2020; 34(10)
[http://dx.doi.org/10.1016/j.jdiacomp.2020.107650] [PMID: 32571685]
[127]
Mader JK, Haas W, Aberer F, et al. Patients with healed diabetic foot ulcer represent a cohort at highest risk for future fatal events. Sci Rep 2019; 9(1): 10325.
[http://dx.doi.org/10.1038/s41598-019-46961-8] [PMID: 31316149]
[128]
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669-701.
[http://dx.doi.org/10.2337/dci18-0033] [PMID: 30291106]
[129]
Giugliano D, Bellastella G, Longo M, et al. Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression. Diabetes Obes Metab 2020; 22(8): 1397-405.
[http://dx.doi.org/10.1111/dom.14047] [PMID: 32250550]
[130]
Dhatariya K, Bain SC, Buse JB, et al. LEADER Publication Committee on behalf of the LEADER Trial Investigators. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care 2018; 41(10): 2229-35.
[http://dx.doi.org/10.2337/dc18-1094] [PMID: 30072400]
[131]
Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7): 644-57.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608]
[132]
Fadini GP, Avogaro A. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 2017; 5(9): 680-1.
[http://dx.doi.org/10.1016/S2213-8587(17)30257-7] [PMID: 28733172]
[133]
Li D, Yang JY, Wang T, Shen S, Tang H. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials. Diabetes Metab 2018; 44(5): 410-4.
[http://dx.doi.org/10.1016/j.diabet.2018.02.001] [PMID: 29506779]
[134]
Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ 2020; 370: m2812.
[PMID: 32843476]
[135]
Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24): 2295-306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260]
[136]
Yuan Z, DeFalco FJ, Ryan PB, et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab 2018; 20(3): 582-9.
[http://dx.doi.org/10.1111/dom.13115] [PMID: 28898514]
[137]
Papadokostaki E, Rizos E, Tigas S, Liberopoulos EN. Canagliflozin and Amputation Risk: Evidence So Far. Int J Low Extrem Wounds 2020; 19(1): 21-6.
[http://dx.doi.org/10.1177/1534734619878090] [PMID: 31698973]
[138]
Food and Drug Administration. FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin Available at: https://www.fda.gov/media/141533/download Accessed 31/08/20202020
[139]
Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6(6)
[http://dx.doi.org/10.1002/14651858.CD007543.pub2] [PMID: 22696371]
[140]
Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002; 19(10): 870-3.
[http://dx.doi.org/10.1046/j.1464-5491.2002.00801.x] [PMID: 12358878]
[141]
Attal N, Cruccu G, Baron R, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17(9): 1113-e88.
[http://dx.doi.org/10.1111/j.1468-1331.2010.02999.x] [PMID: 20402746]
[142]
Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76(20): 1758-65.
[http://dx.doi.org/10.1212/WNL.0b013e3182166ebe] [PMID: 21482920]
[143]
National Institute for Health and Clinical Excellence (NICE) Neuropathic pain-pharmacological management: the pharmacological management of neuropathic pain in adults in nonspecialist settings Available at: http://www.nice.org.uk/guidance/cg1732013
[144]
Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015; 21(Suppl. 1): 1-87.
[145]
Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40(1): 136-54.
[http://dx.doi.org/10.2337/dc16-2042] [PMID: 27999003]
[146]
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14(2): 162-73.
[http://dx.doi.org/10.1016/S1474-4422(14)70251-0] [PMID: 25575710]
[147]
Tesfaye S, Vileikyte L, Rayman G, et al. Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011; 27(7): 629-38.
[http://dx.doi.org/10.1002/dmrr.1225] [PMID: 21695762]
[148]
Gandhi RA, Selvarajah D. Understanding and treating painful diabetic neuropathy: time for a paradigm shift. Diabet Med 2015; 32(6): 771-7.
[http://dx.doi.org/10.1111/dme.12755] [PMID: 25818649]
[149]
Schwartz S, Etropolski MS, Shapiro DY, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig 2015; 35(2): 95-108.
[http://dx.doi.org/10.1007/s40261-014-0249-3] [PMID: 25503082]
[150]
Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”-a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013; 154(12): 2616-25.
[http://dx.doi.org/10.1016/j.pain.2013.05.043] [PMID: 23732189]
[151]
Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374(9697): 1252-61.
[http://dx.doi.org/10.1016/S0140-6736(09)61081-3] [PMID: 19796802]
[152]
Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002; 18(5): 297-301.
[http://dx.doi.org/10.1097/00002508-200209000-00004] [PMID: 12218500]
[153]
Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study. J Pain 2017; 18(1): 42-53.
[http://dx.doi.org/10.1016/j.jpain.2016.09.008] [PMID: 27746370]
[154]
Rayman G, Baker NR, Krishnan ST. Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care 2003; 26(9): 2697-8.
[http://dx.doi.org/10.2337/diacare.26.9.2697-a] [PMID: 12941745]
[155]
Hameed S. Nav1.7 and Nav1.8: Role in the pathophysiology of pain. Mol Pain 2019; 151744806919858801
[http://dx.doi.org/10.1177/1744806919858801] [PMID: 31172839]
[156]
Tibbs GR, Posson DJ, Goldstein PA. Voltage-Gated Ion Channels in the PNS: Novel Therapies for Neuropathic Pain? Trends Pharmacol Sci 2016; 37(7): 522-42.
[http://dx.doi.org/10.1016/j.tips.2016.05.002] [PMID: 27233519]
[157]
Shinobu L, Polydefkis M, Lauria G, Faber C, Freeman R, Steiner D, et al. CONVEY, A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study Design of Vixotrigine for the Treatment of Pain in Participants With Confirmed Small Fiber Neuropathy (P2.6-068). Neurology 2019; 92(Suppl. 15): P2.6-068.
[158]
Kushnarev M, Pirvulescu IP, Candido KD, Knezevic NN. Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers. Expert Opin Investig Drugs 2020; 29(3): 259-71.
[http://dx.doi.org/10.1080/13543784.2020.1728254] [PMID: 32070160]
[159]
Sumpio BE, Armstrong DG, Lavery LA, Andros G. SVS/APMA writing group. The role of interdisciplinary team approach in the management of the diabetic foot: a joint statement from the Society for Vascular Surgery and the American Podiatric Medical Association. J Vasc Surg 2010; 51(6): 1504-6.
[http://dx.doi.org/10.1016/j.jvs.2010.04.010] [PMID: 20488327]
[160]
Eleftheriadou I, Tentolouris A, Tentolouris N, Papanas N. Advancing pharmacotherapy for diabetic foot ulcers. Expert Opin Pharmacother 2019; 20(9): 1153-60.
[http://dx.doi.org/10.1080/14656566.2019.1598378] [PMID: 30958725]
[161]
Bus SA, Armstrong DG, Gooday C, et al. International Working Group on the Diabetic Foot (IWGDF). Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36(Suppl. 1)
[http://dx.doi.org/10.1002/dmrr.3274] [PMID: 32176441]
[162]
Lazzarini PA, Jarl G, Gooday C, et al. Effectiveness of offloading interventions to heal foot ulcers in persons with diabetes: a systematic review Diabetes Metab Res Rev 2020; 36(Suppl. 1)
[http://dx.doi.org/10.1002/dmrr.3275] [PMID: 32176438]
[163]
Jeffcoate WJ, Bus SA, Game FL, Hinchliffe RJ, Price PE, Schaper NC. International Working Group on the Diabetic Foot and the European Wound Management Association. Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality. Lancet Diabetes Endocrinol 2016; 4(9): 781-8.
[http://dx.doi.org/10.1016/S2213-8587(16)30012-2] [PMID: 27177729]
[164]
Game F, Jeffcoate W, Tarnow L, Day F, Fitzsimmons D, Jacobsen J. The LeucoPatch® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial. Trials 2017; 18(1): 469.
[http://dx.doi.org/10.1186/s13063-017-2216-9] [PMID: 29017535]
[165]
Edmonds ME, Bodansky HJ, Boulton AJM, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair Regen 2018; 26(2): 228-37.
[http://dx.doi.org/10.1111/wrr.12630] [PMID: 29617058]
[166]
Game F. Treatment strategies for neuroischaemic diabetic foot ulcers. Lancet Diabetes Endocrinol 2018; 6(3): 159-60.
[http://dx.doi.org/10.1016/S2213-8587(17)30439-4] [PMID: 29275069]
[167]
Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen 2016; 24(1): 112-26.
[http://dx.doi.org/10.1111/wrr.12391] [PMID: 26663430]
[168]
Petrova NL. The Charcot Foot Revisited: How the New Pathogenetic Findings Explain the Clinical Course of the Disease. The Diabetic Foot Syndrome 2018; 26: 48-59.

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy